Inve US ▾
EWEW

Edwards Lifesciences (EW) Q4 FY24 earnings call

Earnings call· Dec 2024 (Q4 FY24)· Health Care· Feb 11, 2025

Source: earnings call transcript

Edwards Lifesciences delivered a strong Q4 FY24, exceeding sales and EPS expectations, primarily driven by robust performance in its TMTT segment and continued adoption of its TAVR technologies. The company is strategically focused on structural heart, with significant investments in R&D and acquisitions, and anticipates continued growth in 2025 and beyond, supported by key clinical catalysts like the EARLY TAVR trial and the EVOQUE launch. Management is committed to expanding profit margins while investing for sustainable growth.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

EW operating KPIs by quarter

EW operating KPIs stated on its earnings calls, by fiscal quarter
KPIThis call Dec 2024 Q4 FY24 Mar 2025 Q1 FY25 Jun 2025 Q2 FY25 Dec 2025 Q4 FY25 Mar 2026 Q1 FY26 Jun 2026 Q2 FY26Change vs prior quarter
Employees
16K It was a year of strong growth and meaningful progress for Edwards as our 16,000 employees advanced life-saving structural heart technologies for patients around the world. Source: earnings call transcript
16K I'd like to thank our 16,000 global employees for their many contributions to advancing patient care. Source: earnings call transcript
16K We are confident that our unique innovation strategy supported by the many important catalysts across our portfolio and the exceptional work of our 16,000 employees around the world will deliver significant value to patients the health care ecosystem and shareholders. Source: earnings call transcript
16K Our talented team of 16,000 employees create, develop and enable treatment of patients globally. Source: earnings call transcript
16K We've built a workplace where our 16,000 employees around the world can stay and grow with us. Source: earnings call transcript
16K Our 16,000 employees around the world are aligned with our vision, inspired by their work and dedicated to delivering exceptional innovation for patients in need. Source: earnings call transcript
0%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.